This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy resistance and improve efficacy, particularly for patients with extramedullary disease. The research aims to provide preclinical support and justification to advance this T-cell imaging approach into clinical application for multiple myeloma and other cancers undergoing immunotherapy with BiTEAs. The award period is from July 11, 2025 to June 30, 2027.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $452.5k | 7/11/25 |